Effect of statin pretreatment on the outcome of ST-segment elevation myocardial infarction in patients without prior history of coronary artery disease

Hellenic Journal of Cardiology

Volumn 54, Issue 6, 2013, Pages 422-428

  Mytas, Dimitrios ^a   Zairis, Michael ^b   Karanasos, Antonios ^c   Kosma, Lamprini ^a   Arsenos, Petros ^a   Tentolouris, Costas ^c   Pitsavos, Christos ^c   Foussas, Stefanos ^b   Stefanadis, Christodoulos ^c   Cokkinos, Dennis ^d  

^a SISMANOGLIO HOSPITAL   (Greece)

^b TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

^d ONASSIS CARDIAC SURGERY CENTER   (Greece)

Author keywords

St elevation myocardial infarction; Statin; Thrombolysis

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CLOPIDOGREL; CREATINE KINASE MB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ADULT; ARTICLE; BLOOD CLOT LYSIS; CARDIOVASCULAR MORTALITY; DIABETES MELLITUS; DRUG DOSE TITRATION; DRUG MEGADOSE; DYSLIPIDEMIA; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; ST SEGMENT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ADULT; AGED; C-REACTIVE PROTEIN; CORONARY ARTERY DISEASE; CREATINE KINASE, MB FORM; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; GREECE; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT DISCHARGE; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 84889637199     PISSN: 11099666     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350: 1495-1504.
2. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352: 1425-1435.
3. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359: 2195-2207.
4. Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering-are they clinically relevant? Eur Heart J. 2003; 24: 225-248.
5. Pagourelias ED, Gossios TD, Tziomalos K, Karagiannis A, Geleris P, Athyros VG. Residual cardiac risk reduction beyond lipid lowering. Hellenic J Cardiol. 2011; 52: 197-203.
6. Spencer FA, Allegrone J, Goldberg RJ, et al. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann Intern Med. 2004; 140: 857-866.
7. Go AS, Iribarren C, Chandra M, et al. Statin and beta-block-er therapy and the initial presentation of coronary heart disease. Ann Intern Med. 2006; 144: 229-238.
8. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110: 227-239.
9. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol. 2004; 44: E1-E211.
10. Schröder R, Wegscheider K, Schröder K, Dissmann R, Mey-er-Sabellek W. Extent of early ST segment elevation resolution: a strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens. A substudy of the International Joint Efficacy Comparison of Thrombolytics (INJECT) trial. J Am Coll Cardiol. 1995; 26: 1657-1664.
11. De Lemos JA, Braunwald E. ST segment resolution as a tool for assessing the efficacy of reperfusion therapy. J Am Coll Cardiol. 2001; 38: 1283-1294.
12. Zairis MN, Lyras AG, Makrygiannis SS, et al. Type 2 diabetes and intravenous thrombolysis outcome in the setting of ST elevation myocardial infarction. Diabetes Care. 2004; 27: 967-971.
13. Lenderink T, Boersma E, Gitt AK, et al. Patients using statin treatment within 24 h after admission for ST-elevation acute coronary syndromes had lower mortality than non-users: a report from the first Euro Heart Survey on acute coronary syndromes. Eur Heart J. 2006; 27: 1799-1804.
14. Okazaki S, Yokoyama T, Miyauchi K, et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation. 2004; 110: 1061-1068.
15. Spencer FA, Fonarow GC, Frederick PD, et al. Early withdrawal of statin therapy in patients with non-ST-segment elevation myocardial infarction: national registry of myocardial infarction. Arch Intern Med. 2004; 164: 2162-2168.
16. Fonarow GC, Wright RS, Spencer FA, et al. Effect of statin use within the first 24 hours of admission for acute myocardi-al infarction on early morbidity and mortality. Am J Cardiol. 2005; 96: 611-616.
17. Bavry AA, Mood GR, Kumbhani DJ, Borek PP, Askari AT, Bhatt DL. Long-term benefit of statin therapy initiated during hospi-talization for an acute coronary syndrome: a systematic review of randomized trials. Am J Cardiovasc Drugs. 2007; 7: 135-141.
18. De Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004; 292: 1307-1316.
19. Hulten E, Jackson JL, Douglas K, George S, Villines TC. The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006; 166: 1814-1821.
20. Kiyokuni M, Kosuge M, Ebina T, et al. Effects of pretreat-ment with statins on infarct size in patients with acute myo-cardial infarction who receive fibrinolytic therapy. Circ J. 2009; 73: 330-335.
21. Koh KK, Son JW, Ahn JY, et al. Comparative effects of diet and statin on NO bioactivity and matrix metalloproteinases in hypercholesterolemic patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2002; 22: e19-23.
22. Zhang RL, Zhang ZG, Chopp M, Zivin JA. Thrombolysis with tissue plasminogen activator alters adhesion molecule expression in the ischemic rat brain. Stroke. 1999; 30: 624-629.
23. Jasińska M, Owczarek J, Orszulak-Michalak D. Statins: a new insight into their mechanisms of action and consequent pleio- tropic effects. Pharmacol Rep. 2007; 59: 483-499.
24. Takarada S, Imanishi T, Ishibashi K, et al. The effect of lipid and inflammatory profiles on the morphological changes of lipid-rich plaques in patients with non-ST-segment elevated acute coronary syndrome: follow-up study by optical coherence tomography and intravascular ultrasound. JACC Car-diovasc Interv. 2010; 3: 766-772.
25. Toutouzas K, Tsiamis E, Karanasos A, et al. Morphological characteristics of culprit atheromatic plaque are associated with coronary flow after thrombolytic therapy: new implications of optical coherence tomography from a multicenter study. JACC Cardiovasc Interv. 2010; 3: 507-514.
26. Tanaka A, Imanishi T, Kitabata H, et al. Lipid-rich plaque and myocardial perfusion after successful stenting in patients with non-ST-segment elevation acute coronary syndrome: an optical coherence tomography study. Eur Heart J. 2009; 30: 1348-1355.
27. Bao N, Minatoguchi S, Kobayashi H, et al. Pravastatin reduces myocardial infarct size via increasing protein kinase C-de-pendent nitric oxide, decreasing oxyradicals and opening the mitochondrial adenosine triphosphate-sensitive potassium channels in rabbits. Circ J. 2007; 71: 1622-1628.
28. Hoffmann R, Haager P, Suliman H, et al. Effect of statin therapy before Q-wave myocardial infarction on myocardial perfusion. Am J Cardiol. 2008; 101: 139-143.
29. Ishii H, Ichimiya S, Kanashiro M, et al. Effects of receipt of chronic statin therapy before the onset of acute myocardial infarction: a retrospective study in patients undergoing primary percutaneous coronary intervention. Clin Ther. 2006; 28: 1812-1819.
30. Iwakura K, Ito H, Kawano S, et al. Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction. Eur Heart J. 2006; 27: 534-539.
31. Celik T, Kursaklioglu H, Iyisoy A, et al. The effects of prior use of atorvastatin on coronary blood flow after primary percutaneous coronary intervention in patients presenting with acute myocardial infarction. Coron Artery Dis. 2005; 16: 321-326.
32. Bell RM, Yellon DM. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol. 2003; 41: 508-515.
33. Lefer AM, Campbell B, Shin YK, Scalia R, Hayward R, Lefer DJ. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation. 1999; 100: 178-184.
34. Wolfrum S, Dendorfer A, Schutt M, et al. Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway. J Cardiovasc Pharmacol. 2004; 44: 348-355.
35. Lev EI, Kornowski R, Vaknin-Assa H, et al. Effect of previous treatment with statins on outcome of patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Am J Cardiol. 2009; 103: 165-169.
36. Cuculi F, Radovanovic D, Eberli FR, Stauffer JC, Bertel O, Erne P. The impact of statin treatment on presentation mode and early outcomes in acute coronary syndromes. Cardiology. 2008; 109: 156-162.
37. Toutouzas K, Synetos A, Karanasos A, et al. Prognostic models for cardiovascular events after successful primary percutaneous coronary intervention. Int J Cardiol. 2012; 158: 168-170.
38. Andrikopoulos G, Tzeis S, Mantas I, et al. Epidemiological characteristics and in-hospital management of acute coronary syndrome patients in Greece: results from the TARGET study. Hellenic J Cardiol. 2012; 53: 33-40.